| Literature DB >> 25561334 |
William F Penwell1, Adam B Shapiro1, Robert A Giacobbe1, Rong-Fang Gu1, Ning Gao1, Jason Thresher1, Robert E McLaughlin1, Michael D Huband1, Boudewijn L M DeJonge1, David E Ehmann1, Alita A Miller2.
Abstract
Sulbactam is a class A β-lactamase inhibitor with intrinsic whole-cell activity against certain bacterial species, including Acinetobacter baumannii. The clinical use of sulbactam for A. baumannii infections is of interest due to increasing multidrug resistance in this pathogen. However, the molecular drivers of its antibacterial activity and resistance determinants have yet to be precisely defined. Here we show that the antibacterial activities of sulbactam vary widely across contemporary A. baumannii clinical isolates and are mediated through inhibition of the penicillin-binding proteins (PBPs) PBP1 and PBP3, with very low frequency of resistance; the rare pbp3 mutants with high levels of resistance to sulbactam are attenuated in fitness. These results support further investigation of the potential clinical utility of sulbactam.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25561334 PMCID: PMC4325763 DOI: 10.1128/AAC.04808-14
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.191